From February 10 to 13, 2026, WHX Labs Dubai took place at the Dubai World Trade Centre, marking a strong opening to the year for KHB and its subsidiary Tianlong. As the Group’s first international exhibition of 2026—held on the eve of the Chinese Year of the Horse—the event carried both symbolic and strategic significance.

The transition of the exhibition from Medlab to WHX Labs Dubai—with its expanded scale and sharper focus on laboratory systems—closely mirrored KHB Group’s own strategic direction. For the first time at this venue, KHB and Tianlong presented a deeply integrated, multi-platform diagnostic offering, highlighting how complementary technologies can function together within a single, coherent solution framework.

Integrated Diagnostics for Diverse Regional Needs

KHB focused on its clinical chemistry, immunoassay, and blood screening platforms, while Tianlong highlighted molecular diagnostics and hygiene monitoring. Together, the Group demonstrated a complete diagnostic pathway—from routine testing to precision diagnostics, and from centralized laboratories to decentralized and point-of-care settings.

Given the strong regional demand for blood safety and infectious disease detection, particular emphasis was placed on flexible, modular configurations that can be adapted to different laboratory scales and operational requirements across the Middle East and surrounding markets.

Flagship Solution | A Full-Chain Blood Screening Platform Setting a New Industry Benchmark

Dual-Platform Blood Screening Strategy: NAT and Chemiluminescence in Complementary Use

At WHX Labs Dubai 2026, KHB presented its second-generation nucleic acid blood screening reagents together with a fully automated NAT blood screening workflow, alongside its chemiluminescence-based serological testing platform.

With internationally competitive analytical sensitivity and multi-level automation, the integrated solution became a key focal point for blood screening professionals at the exhibition.

On the reagent performance side, KHB’s second-generation NAT blood screening reagents attracted strong attention for their ultra-low limits of detection:

? HBV: as low as 1.087 IU/mL

? HCV: as low as 3.385 IU/mL

? HIV-1/2: as low as 12.957 IU/mL and 22.592 IU/mL, respectively

These performance indicators reach internationally advanced levels, reinforcing the robustness of the molecular screening solution.

On the platform side, KHB’s fully automated NAT blood screening line enables end-to-end automation, covering the entire process from sample reception to PCR system setup, without manual intervention.

To meet the needs of blood centers at different operational scales, KHB offers multiple platform options, including:

? Panall 8000: a low-to-medium throughput, sample-in/result-out system

? Aurora PANA X6: a high-throughput platform supporting both individual and pooled testing

Together, these systems provide a tiered and scalable configuration that aligns with the stratified requirements of blood centers at different levels.

The chemiluminescence platform forms an essential component of the overall blood screening strategy. The Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer, compatible with serological assays for HBV, HCV, HIV, and syphilis, supports random-access single-sample testing, STAT prioritization, and throughput of up to 150 tests per hour.

Combined with NAT confirmation, it delivers a dual-platform blood screening solution that integrates immunoassay screening with molecular verification.

ELISA & POCT Platforms | Strengthening the Foundation of Blood Screening

In the field of ELISA-based testing, KHB brings more than four decades of technical expertise and industrial experience. Its ELISA reagent portfolio is widely recognized for high sensitivity, high specificity, and excellent batch-to-batch consistency, and continues to serve as a core technology platform for infectious disease screening in blood centers and public health laboratories worldwide.

In the POCT segment, KHB Group presented the iGenebox 3A Automated Nucleic Acid Detection System for its first international appearance. Independently developed by Tianlong, the iGenebox 3A is a POCT molecular platform based on real-time fluorescence PCR technology, capable of completing a full “sample-in, result-out” workflow within 12-30 minutes.

With the ability to detect up to 24 target genes per run, the system offers an efficient solution for rapid, on-site screening and multiplex detection of infectious diseases.

A Confident Start to 2026, with a Steady Global Outlook

As the first international exhibition of the year, WHX Labs Dubai 2026 generated strong interest in KHB Group’s full-solution offerings, with visitors expressing clear intent for follow-up discussions and localized cooperation. This enthusiastic response reinforces the group’s confidence in its global expansion roadmap for 2026.

As a Chinese proverb says: “A fine horse knows the long road ahead and needs no whip to move forward.”Looking ahead, KHB Group will continue to strengthen multi-platform collaboration, advance regional customization strategies, and work closely with global partners to deliver locally relevant diagnostic solutions—moving forward together toward a shared future.